Life Science REIT (LABS) Share Price, News & Analysis

Company Overview

Life Science REIT plc (the Company) is a closed-ended Real Estate Investment Trust (REIT) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange. The registered office of the Company is located at 6th Floor, 65 Gresham Street, London, EC2V 7NQ.

Key Stats

• Today's Range: 41 to 41.80
• 50-Day Range: 31.50 to 42.60
• 52-Week Range: 31.30 to 68.20
• Volume: 596,716 shs
• Average Volume: 1.03 million shs
• Market Capitalization: £143.50 million
• P/E Ratio: N/A
• Dividend Yield: 4.88%
• Price Target: GBX 46.50
• Consensus Rating: Moderate Buy

LABS Stock Analysis - Frequently Asked Questions

How have LABS shares performed this year?

Life Science REIT's stock was trading at GBX 63.20 at the beginning of 2024. Since then, LABS stock has decreased by 35.1% and is now trading at GBX 41.
View the best growth stocks for 2024 here.

How do I buy shares of Life Science REIT?

Shares of LABS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Company Calendar

• Ex-Dividend for 10/31 Dividend: 10/03/2024
• Dividend Payable: 10/31/2024
• Today: 11/17/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Real Estate
• Industry: REIT - Healthcare Facilities
• Sub-Industry: N/A
• Current Symbol: LON:LABS
• CUSIP: N/A
• CIK: N/A
• Web: www.lifesciencereit.co.uk
• Phone: 44-20-7945-9566
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 46.50
• High Stock Price Target: GBX 57
• Low Stock Price Target: GBX 36
• Potential Upside/Downside: +13.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-21,710,000.00
• Net Margins: -108.85%
• Pretax Margin: N/A
• Return on Equity: -7.20%
• Return on Assets: 1.25%

Debt

• Debt-to-Equity Ratio: 38.03
• Current Ratio: 1.45
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: £19.94 million
• Price / Sales: 7.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 81 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 350,000,000
• Free Float: N/A
• Market Cap: £143.50 million
• Optionable: Not Optionable
• Beta: 0.08